NCT05355168 2024-12-31
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Anhui Provincial Hospital
Phase 2 Completed
Anhui Provincial Hospital
Henan Cancer Hospital
Fujian Cancer Hospital
Henan Cancer Hospital
Fujian Cancer Hospital